AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.595

-0.015-2.46%

Volume:3.83M

Turnover:2.34M

Market Cap:332.86M

PE:-13.46

High:0.635

Open:0.605

Low:0.595

Close:0.610

Loading ...

Overview Company News Filings

Company Profile

Company Name:

DIMERIX LTD

Exchange:

ASX

Establishment Date:

- -

Employees:

- -

Office Location:

425 Smith Street,Fitzroy,Victoria,Australia

Website:

http://dimerix.com

Zip Code:

3065

Phone:

Fax:

61 8 9388 8256

Introduction:

Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.595,"timestamp":1747116720000,"preClose":0.61,"halted":0,"volume":3832061,"delay":0,"nameEN":"DIMERIX LTD","floatShares":438634329,"shares":559426763,"eps":-0.044195,"marketStatus":"Not Yet Opened","change":-0.015,"latestTime":"05-13 16:12:00 AEST","open":0.605,"high":0.635,"low":0.595,"amount":2342231,"amplitude":0.065574,"askPrice":0.595,"askSize":6620,"bidPrice":0.59,"bidSize":273024,"shortable":3,"etf":0,"ttmEps":-0.044195,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747180800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.61,"openAndCloseTimeList":[[1747094400000,1747116000000]],"volumeRatio":0.719151,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":438634329,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.719151,"shares":559426763,"dividePrice":0,"high":0.635,"amplitude":0.065574,"preClose":0.61,"low":0.595,"week52Low":0.3,"pbRate":"46.44","psRate":"451.11","week52High":0.785,"institutionHeld":0,"latestPrice":0.595,"committee":0.952654,"eps":-0.044195,"divideRate":0,"volume":3832061,"delay":0,"ttmEps":-0.044195,"open":0.605,"prevYearClose":0.34,"prevWeekClose":0.66,"prevMonthClose":0.48,"prevQuarterClose":0.415,"fiveDayClose":0.695,"twentyDayClose":0.375,"sixtyDayClose":0.505},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":23928564,"address":"425 Smith Street,Fitzroy,Victoria,Australia","zipCode":"3065","officePhone":"1300 813 321","officeFax":"61 8 9388 8256"},"stockCompanyDetail":{"websiteUrl":"http://dimerix.com","stockEarnings":[{"period":"1week","weight":-0.1439},{"period":"1month","weight":0.5063},{"period":"3month","weight":0.1333},{"period":"6month","weight":0.5867},{"period":"1year","weight":0.8308},{"period":"ytd","weight":0.75}],"compareEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":0.0514},{"period":"3month","weight":0.0345},{"period":"6month","weight":0.1389},{"period":"1year","weight":0.1401},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.096283},{"month":2,"riseRate":0.5,"avgChangeRate":0.059355},{"month":3,"riseRate":0.4,"avgChangeRate":0.044676},{"month":4,"riseRate":0.3,"avgChangeRate":0.039714},{"month":5,"riseRate":0.555556,"avgChangeRate":0.055555},{"month":6,"riseRate":0.888889,"avgChangeRate":0.201887},{"month":7,"riseRate":0.3,"avgChangeRate":0.076159},{"month":8,"riseRate":0.3,"avgChangeRate":-0.085696},{"month":9,"riseRate":0.4,"avgChangeRate":0.190165},{"month":10,"riseRate":0.1,"avgChangeRate":-0.102185},{"month":11,"riseRate":0.2,"avgChangeRate":0.026693},{"month":12,"riseRate":0.5,"avgChangeRate":0.055449}],"exchange":"ASX","name":"DIMERIX LTD","nameEN":"DIMERIX LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[]}}